ATAI vs ATHE

AtaiBeckley Inc. vs Alterity Therapeutics Limited — Valuation Comparison 2026

ATAI

Biotechnology
AtaiBeckley Inc.
Quality
4.9
out of 10
Value Trap
Price
$4.41
Last close
Models
5/13
Active
VS

ATHE

Biotechnology
Alterity Therapeutics Limited
Quality
1.8
out of 10
Value Trap
Price
$4.08
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ATAI Fair ValueATAI Upside ATHE Fair ValueATHE Upside
Bayesian DCF Intrinsic $1.04 -76.5% $1.08 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.35 -46.8% $0.18 -95.5%
Dynamic NAV Asset-Based $0.41 -90.6% $1.07 -73.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATAI vs ATHE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATAI vs ATHE — Which Stock Is More Undervalued?

ATAI scores higher with a 4.9/10 quality rating vs ATHE's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AtaiBeckley Inc. (ATAI) and Alterity Therapeutics Limited (ATHE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATAI currently trades at $4.41 with a QOC of 4.9/10, while ATHE trades at $4.08 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).